Krystal Biotech, Inc.

KRYS • Biotechnology

$321.50

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$9.86B

Growth

—

Cash Flow

2/5

Trend

Volatile

Evidence

Stable or improving margins · 52.6%Positive revenue growth · 168.3%Positive free cash flow · 6.53Manageable debt level · 0.01Healthy liquidity · 9.95

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$321.50

Change0.00%

Shares Out30.66M

Market Cap$9.86B

Enterprise Value$9.01B

52W Range132.31 - 382.54

Beta0.54

P/E40.82

P/S22.38

P/B7.25

P/FCF38.23

EV/Sales20.46

Price$321.50

Change0.00%

Shares Out30.66M

Market Cap$9.86B

Enterprise Value$9.01B

52W Range132.31 - 382.54

Beta0.54

P/E40.82

P/S22.38

P/B7.25

P/FCF38.23

EV/Sales20.46

EV/EBITDA42.78

EV/FCF34.96

Earnings Yield2.45%

FCF Yield2.62%

Dividend Yield0.00%

Gross Margin92.61%

Oper. Margin41.45%

Profit Margin52.64%

Debt/Eq0.01

Current Ratio9.95

Quick Ratio9.56

Target$395.20

Target Upside22.92%

Target Median$400.00

Target Range300.00 - 474.00

Volume529.73K

Avg Volume435.78K

EPS Surprise0.38

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

90/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

30/100

Why this score▼

Stable or improving margins · 52.6%Positive revenue growth · 168.3%Positive free cash flow · 6.53Manageable debt level · 0.01Healthy liquidity · 9.95

Analyst view

Analyst sentiment and price target

KRYS

Analyst sentiment

Based on 17 analyst votes · 2026-10-20

100/100

Bullish

Hold

Bearish

Price Target

2026-08-05

Low

$300.00

Mean

$364.50

Median

$342.00

High

$474.00

Company Overview

IPO: 9/20/2017

Industry: Biotechnology

P/B i: 7.25

Debt / Equity i: 0.01

Operating Margin: 41.45%

Net Margin: 52.64%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.01

Current Ratio: 9.95

Quick Ratio: 9.56

Status: Good

Insider Transactions

Recent executive and insider activity

Thomas John Charles

Transaction: 06/25/2026

SELL

Change

-1,000

Price

$347.27

Filing

06/26/2026

Type

SELL

Thomas John Charles

Transaction: 06/25/2026

SELL

Change

-1,000

Price

$179.25

Filing

06/26/2026

Type

SELL

Krishnan Krish S

Transaction: 06/04/2026

SELL

Change

-40

Price

$312.23

Filing

06/05/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Thomas John Charles	SELL	-1,000	$347.27	06/25/2026	06/26/2026
Thomas John Charles	SELL	-1,000	$179.25	06/25/2026	06/26/2026
Krishnan Krish S	SELL	-40	$312.23	06/04/2026	06/05/2026
Krishnan Suma	SELL	-240	$311.65	06/04/2026	06/05/2026
Thomas John Charles	SELL	-642	$302.03	05/26/2026	05/27/2026
Krishnan Krish S	SELL	-920	$266.56	03/04/2026	03/06/2026
Krishnan Suma	SELL	-1,700	$266.42	03/04/2026	03/06/2026
Thomas John Charles	OTHER	+1,250	Not reported	03/01/2026	03/06/2026
Thomas John Charles	OTHER	+32,400	$52.21	03/01/2026	03/06/2026
Thomas John Charles	OTHER	0	Not reported	03/01/2026	03/06/2026
Goux Laurent Louis Jean	OTHER	+674	Not reported	03/01/2026	03/06/2026
Goux Laurent Louis Jean	OTHER	+19,000	$52.21	03/01/2026	03/06/2026
Goux Laurent Louis Jean	OTHER	0	Not reported	03/01/2026	03/06/2026
ROMANO KATHRYN	SELL	-750	$267.60	03/02/2026	03/03/2026
JANNEY DANIEL	SELL	-2,373	$276.17	02/27/2026	03/03/2026
Krishnan Krish S	SELL	-26,250	Not reported	02/27/2026	03/03/2026
Krishnan Krish S	SELL	-5,725	Not reported	02/27/2026	03/03/2026
Krishnan Krish S	BUY	+45,249	$275.64	02/27/2026	03/03/2026
Krishnan Krish S	SELL	-10,236	$275.64	02/27/2026	03/03/2026
Krishnan Suma	BUY	+7,256	Not reported	02/27/2026	03/03/2026

About the Company

Krystal Biotech, Inc.

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Source - link

Peers

ACLX ALKS ARWR CRSP MTSR PCVX PTCT PTGX TFX TGTX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.

Zacks Investment Research

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect KB113 injections were well tolerated by Gorlin syndrome patients; all reported adverse events were mild to moderate in severity and transient in nature Data will be presented by study investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, October 15-17, 2026 PITTSBURGH, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today a positive clinical update supporting initial proof of concept for KB113, an intratumoral immunotherapy designed to drive sustained, localized expression of interleukin-2 (IL-2) and interleukin-12 (IL-12) in the tumor microenvironment and promote systemic immune-mediated tumor clearance, in the treatment of basal cell carcinomas (BCCs) in patients with Gorlin syndrome: Broad antitumor responses were detected in all three Gorlin syndrome patients treated with KB113, with over 80% of assessed BCC lesions reducing in size; Responses were observed in both injected and non-injected lesions, including substantial regression in lesions that were not directly injected with KB113, consistent with an abscopal effect; and Complete clearance of an injected lesion was also confirmed histologically for each of the three patients treated with KB113. Gorlin syndrome is a genetic disease characterized by a greatly increased risk of developing BCCs.

GlobeNewsWire

2,490 Shares in Krystal Biotech, Inc. $KRYS Purchased by Terra Nova Asset Management LLC

Terra Nova Asset Management LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,490 shares of the company's stock, valued at approximately $828,000. Several other institutional

Defense World

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2 revenue and expanding global reach. KRYS maintains a $1.1bn cash position, a 40% operating margin, and trades at ~12x forward P/E, supporting attractive valuation.

Seeking Alpha

Breakfast News: Week in Review

Yields hit a 24-year high as SpaceX borrows $40 billion for Nvidia chips, and more…

Fool - Investing News

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-04	1.45	1.83	0.38
2026-02-17	1.62	1.7	0.08
2025-11-03	1.12	2.66	1.54
2025-08-04	1.08	1.29	0.21
2025-05-06	1.38	1.2	-0.18
2025-02-19	1.29	1.52	0.23
2024-11-04	0.9	0.91	0.01
2024-08-05	0.5	0.86	0.36
2024-05-06	0.15	0.03	-0.12
2024-02-26	-0.38	0.3	0.68
2023-11-06	-1.1	-0.67	0.43
2023-08-07	-0.42	-1.25	-0.83